CenExel RCA

What CenExel RCA does

CenExel RCA, operating under the legal name CenExel Clinical Research, is a privately held clinical research site network founded in 2011 and headquartered in Hollywood, United States. The company operates an integrated network of research centers spanning 360,000+ square feet with 600+ beds across multiple U.S. metropolitan locations, conducting complex clinical trials for pharmaceutical and biotechnology sponsors. Its therapeutic portfolio covers central nervous system indications (schizophrenia, depression, Alzheimer's disease, acute pain), Clinical Sciences for early-phase pharmaceutical development, patient recruitment, ethnic bridging studies, first-in-human studies, psychedelic research, and SAD/MAD studies. The company reports that its patient-centric recruitment model consistently exceeds 100% of enrollment targets.

The company's core technology stack comprises two components: an advanced clinical research network of expert investigators and modern facilities, and a proprietary mobile application available on iOS (App Store ID 6740370118) and Android that connects patients to relevant clinical trials. The mobile app functions as a direct-to-patient recruitment and engagement layer, supporting the B2B sponsor relationship by improving enrollment velocity. CenExel engages sponsors through a formal RFI/RFP process managed by a dedicated Strategic Partnerships Team that commits to reviewing every request within 24 hours — a relationship-driven, enterprise field-sales motion targeting large pharmaceutical and biotechnology organizations.

The revenue model is professional-services based: CenExel is paid by pharmaceutical and biotechnology sponsors on a contract basis to conduct clinical trials at its research sites, with pricing negotiated through custom RFPs rather than publicly disclosed. Distribution is dual-channel — direct enterprise sales to pharma/biotech sponsors and a self-serve patient recruitment portal (cenexelclinicaltrials.com) plus mobile-app stores for patient acquisition. The company is led by founder Peter Ventre, who serves as Founder & Principal Investigator.

Name

CenExel RCA

Legal name

CenExel Clinical Research

Website

https://cenexelresearch.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

CenExel RCA (CenExel Clinical Research) is a private U.S. clinical research site network conducting complex trials for pharmaceutical and biotechnology sponsors across CNS, first-in-human, psychedelic, and ethnic bridging studies, supported by 600+ beds and a patient-facing mobile app.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical research services
• Clinical trial site network
• Early phase drug development
• Patient recruitment services
• CNS clinical trials

Headquarters

HQ city

Hollywood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Research Services: CenExel generates revenue by providing clinical research services to pharmaceutical and biotechnology companies. The company operates as a site network conducting clinical trials under contract, likely on a per-study or project-based fee structure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

CenExel RCA operates an integrated clinical research site network that conducts clinical trials on behalf of pharmaceutical and biotechnology sponsors. The company leverages 360,000+ square feet of research facilities with 600+ beds across diverse U.S. metropolitan areas, therapeutic expertise in Central Nervous System disorders, Clinical Sciences, and specialized study types (First in Human, ethnic bridging, psychedelics, SAD/MAD), and a patient-centric recruitment platform that consistently exceeds 100% enrollment targets. Supporting channels include the proprietary CenExel Mobile Application and a dedicated clinical trials portal for patient engagement.

Product overview

CenExel is a clinical research site network that provides a unified platform of research services to pharmaceutical and biotechnology partners. The core offering consists of the CenExel Clinical Research Network—a coordinated network of research centers—and the CenExel Mobile App, a patient-facing mobile application that enables users to discover and enroll in clinical trials. The network supports multiple therapeutic areas including Central Nervous System conditions (schizophrenia, depression, Alzheimer's disease, acute pain), clinical sciences, patient recruitment, ethnic bridging, first-in-human studies, psychedelics research, and SAD/MAD studies. Together, these products form an integrated ecosystem designed to accelerate clinical development from site selection through study close-out.

Differentiator

Problem solved

Functional benefit

Products and services

• CenExel Clinical Research Network Integrated network of clinical research centers partnering with pharmaceutical and biotechnology organizations to conduct clinical trials, providing expert investigators, modern facilities, and participant-focused programs across multiple therapeutic areas.
• CenExel Mobile App Patient-facing mobile application available on iOS and Android that connects users with relevant clinical trials tailored to their health needs and enables them to discover and join studies directly from their devices.
• Patient Recruitment Services Patient-centric recruitment services for clinical trials, designed to consistently exceed 100% of patient target enrollment goals and accelerate clinical development timelines for sponsor studies.
• Central Nervous System Clinical Trials Clinical research services specializing in CNS indications including Schizophrenia, Depression, Alzheimer's Disease, and Acute Pain for pharmaceutical and biotechnology sponsors.
• Clinical Sciences / Early Phase Drug Development Early phase pharmaceutical development clinical research services delivered through CenExel's Clinical Sciences division, supporting novel therapeutic development programs.
• Specialized Study Types (First in Human, Ethnic Bridging, Psychedelics, SAD/MAD) Clinical research services for specialized and complex study designs, including First in Human trials, Ethnic Bridging studies, Psychedelics research, and Single Ascending Dose / Multiple Ascending Dose (SAD/MAD) studies.

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Accel Research Sites: Multi-therapeutic U.S. clinical research site network conducting Phase I–IV trials for pharma/biotech. Directly comparable to CenExel on business model, customer base, and therapeutic breadth.
• Velocity Clinical Research: Multi-site clinical research site network in the U.S. that runs Phase I–IV trials for pharma/biotech sponsors with focused therapeutic expertise. Closely comparable to CenExel in business model (site network, per-study B2B contracts), therapeutic breadth, and patient recruitment emphasis.
• Elligo Health Research: U.S. clinical research site network leveraging technology-enabled patient identification and direct-to-patient recruitment. Operates a similar site-network CRO model to CenExel, with overlapping pharma/biotech customer base and shared focus on accelerating enrollment.
• Flourish Research: Independent U.S. clinical research site network running multi-therapeutic trials for pharmaceutical sponsors. Comparable in scale, therapeutic specialization, and B2B contract model to CenExel.

Broad incumbents

• Medpace: Mid-to-large full-service CRO with strong site-management and Phase I–III trial capabilities, particularly in specialty therapeutic areas. Competes with CenExel for sponsor trial placements but offers a broader global, full-service portfolio.
• IQVIA: Largest global CRO with integrated clinical operations, real-world data, and technology-enabled patient recruitment. Competes with CenExel for sponsor budgets and offers a far broader service portfolio across geographies.
• Worldwide Clinical Trials: Mid-sized global CRO with strong CNS and specialty therapeutic expertise. Comparable to CenExel on therapeutic focus (especially CNS) while offering a broader global Phase I–IV service portfolio.
• ICON plc: One of the world's largest CROs with global Phase I–IV capabilities, including site management and patient recruitment services. Overlaps with CenExel on clinical trial execution and recruitment, but operates at far greater scale and geographic breadth.
• Syneos Health: Large full-service biopharmaceutical solutions organization offering clinical development and site/sponsor services globally. Overlaps with CenExel on clinical trial execution and patient recruitment.
• Charles River Laboratories: Major CRO/CDMO with strong early-phase development and clinical trial services, including CNS and specialty therapeutic capabilities. Comparable to CenExel on early-phase and CNS offerings, but with much broader service and global scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/RCATrials

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CenExel RCA